SOLMETEX, LLC ACQUIRES IMPLADENT LTD.
Combination Adds Attractive Regenerative Dental Technology Products
MARLBOROUGH, Mass. and QUEENS, N.Y. -- Solmetex, LLC, the dental industry's leading provider of dental waterline products and modern dental isolation solutions, today announced that it has acquired Impladent Ltd., a provider of a broad range of innovative and affordable regenerative materials including bone grafts and resorbable membranes used in tooth extraction procedures. The combination creates a diversified dental company with a strong portfolio of leading products across dental waterline treatment, modern dental isolation, and regenerative biomaterials. The combined Company will continue its commitment to strengthen and expand partnerships built with individual dental practices and Dental Service Organizations across the U.S. and global dental markets.
Impladent brings nearly 40 years of excellence and leadership in regenerative dental solutions and its products are highly regarded by dentists for their efficacy and ease-of-use. Impladent's flagship product, the OsteoGen® Plug, is a one-step solution for socket preservation without the need for a membrane. As part of the Solmetex platform, Impladent will continue to expand and strengthen its ability to develop and market innovative products.
Gene Dorff, Solmetex's Chief Executive Officer, stated, "We are proud to partner with a leader and innovator in regenerative dental technology. We believe the addition of Impladent to our offering will unlock meaningful growth in new areas. I look forward to the opportunity to collaborate with the Impladent team and execute on our plans for future expansion."
Andrew Valen, Impladent's President, offered, "We are eager to partner with Solmetex to help launch our next phase of growth and accelerate expansion into new markets with new products." Maurice Valen, Impladent Founder and CEO, added, "After nearly 40 years operating as a family company, we are confident that Solmetex is the right partner at the right time to take Impladent to the next level."
Solmetex's existing investors, including Avista Capital Partners ("Avista"), supported the transaction.
Financial terms of the transaction were not disclosed.